(Medical Xpress) -- This week the Journal of the American Medical Association published a study with unfortuate news for the millions of people who suffer from multiple sclerosis. In the large study, a therapy known as interferon ...
Jul 23, 2012
0
0
(Medical Xpress)—Multiple sclerosis (MS) patients sometimes experience "natural" improvements in disability at least over the short term, according to a new study led by researchers at the University of British Columbia ...
Oct 18, 2012
0
0
A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with COVID-19 pneumonia. In addition, ...
Oct 18, 2021
0
54
Patients who rely on recombinant, protein-based drugs must often endure frequent injections, often several times a week, or intravenous therapy. Researchers at Children's Hospital Boston demonstrate the possibility that blood ...
Nov 15, 2011
0
0
Omega-3 fatty acid supplements were not associated with beneficial effects on disease activity in patients with relapsing-remitting multiple sclerosis, according to a report of a randomized controlled trial published Online ...
Apr 23, 2012
0
0
Monash University researchers have gained new insight into the early stages of our immune response, providing novel pathways to develop treatments for diseases from multiple sclerosis to cancer.
Jul 21, 2013
0
0
Tests of a new long-acting version of one of the oldest multiple sclerosis (MS) drugs on the market show it worked significantly better than placebo in reducing the number of patient relapses and developments of new or active ...
Apr 30, 2014
0
0
Donald Trump's brief stay in hospital in early October raised awareness—once again—of the variety of treatments being investigated for COVID-19.
Oct 22, 2020
0
4
Details of a treatment that could help asthmatics fight infections that trigger 80% of asthma attacks, developed by University of Southampton spin-out company Synairgen, will be presented to European respiratory experts on ...
Aug 31, 2012
0
0
Since its approval in 2011, the multiple sclerosis drug fingolimod (Gilenya) has already undergone three early benefit assessments, all of which were mainly based on the approval study TRANSFORMS. After a new modification ...
Mar 8, 2016
0
9
